Omaveloxolone Patent Expiration
Omaveloxolone is used for treating Friedrich's ataxia by activating the NRF2 pathway to reduce oxidative stress in adults and adolescents aged 16 years and older. It was first introduced by Reata Pharmaceuticals Inc
Omaveloxolone Patents
Given below is the list of patents protecting Omaveloxolone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Skyclarys | US8993640 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | Apr 24, 2033 | Reata Pharms |
| Skyclarys | US9701709 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | Apr 24, 2033 | Reata Pharms |
| Skyclarys | US8124799 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | Dec 03, 2029 | Reata Pharms |
| Skyclarys | US11091430 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 | Apr 20, 2029 | Reata Pharms |
| Skyclarys | US11919838 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | Apr 20, 2029 | Reata Pharms |
| Skyclarys | US8440854 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 | Apr 20, 2029 | Reata Pharms |
| Skyclarys | US9670147 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | Apr 20, 2029 | Reata Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Omaveloxolone's patents.
Latest Legal Activities on Omaveloxolone's Patents
Given below is the list recent legal activities going on the following patents of Omaveloxolone.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US8124799 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US8440854 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US9670147 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US9701709 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US11091430 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US8993640 |
| Recordation of Patent eGrant | 05 Mar, 2024 | US11919838 |
| Recordation of Patent Grant Mailed Critical | 05 Mar, 2024 | US11919838 |
| Patent eGrant Notification | 05 Mar, 2024 | US11919838 |
| Email Notification Critical | 05 Mar, 2024 | US11919838 |
Omaveloxolone's Family Patents
